No abstract available.
Selective Estrogen Receptor Modulators*

The antiarrhythmic efficacy if low dose amiodarone treatment was studied in 30 cases of ventricular premature beats(VPBs). Amiodarone was administered 600mg daily in three divided doses for for initial 7-10 days as loadihg dosage,then 100-200mg once daily as maintenance. The results obtained were as follow : 1) The complete control of VPBs was achieved by amiodarone treatment in 90%, 27cases of 30 cases(all 11 cases with simple VPBs and 16 cases of the remainders with complex VPBs). 2) The QT interval and QTc were significantly prolonged, whereas heart rate was reduced significantly after amiodarone treatment. 3) In 27 cases of responder, the frequency of VPBs began to decrease overtly 2-3 days after amiodarone administration, then relatively stablized in 6 days, and complete cnotrol of VPBs was achieved in all cases about 10 days after treatment. 4) No significant side-reaction was observed except the decrease of serm T3 level after treatment.
Amiodarone* ; Arrhythmias, Cardiac* ; Heart Rate ; Selective Estrogen Receptor Modulators

We report five cases of pattern alopecia in female patients who are undergoing hormonal anticancer therapy for the prevention of recurrence of breast cancer after surgery. Three patients demonstrated male pattern alopecia with receding frontal hairlines, and two patients demonstrated female pattern alopecia without receding hairlines. The detailed clinical history showed that the pattern alopecia of the patients developed after the full recovery of global hair loss of the entire scalp due to previous cytotoxic chemotherapy. All of the adjuvant hormonal anticancer drugs that were used in the patients are antiestrogenic agents, either aromatase inhibitors or selective estrogen receptor modulators. Considering androgen effect on the hair follicles of the fronto-parietal scalp, the androgen-estrogen imbalance caused by the drugs was thought to be the reason for the onset of pattern alopecia in the patients. In general, alopecia that develops during cytotoxic chemotherapy is well known to both physicians and patients; however, the diagnosis of pattern alopecia during hormonal anticancer therapy in breast cancer patients seems to be overlooked.
Alopecia* ; Androgens ; Aromatase Inhibitors ; Breast Neoplasms* ; Diagnosis ; Drug Therapy ; Estrogen Receptor Modulators ; Estrogens ; Female ; Hair ; Hair Follicle ; Humans ; Recurrence ; Scalp ; Selective Estrogen Receptor Modulators

Since adult human skin can be grown in chernically defined medium without serum, the skin organ culture has gained a great interest as a method for studies concerning skin biology, pharmacology and toxicology. however, serum supplementation has extensively been used to improve the viahility of tissue culture. This study was undertaken to evaluate the effect of serum on the histologic changes ohserved during the organ culture of the normal human skin. The general architecture of the skin was well maintained for 6 days with or without seru. After then, fetal calf serum or autologous human serum was found to enhance the viability of the epidermis. A confluent layer of necrotic spinous ceils was ovserved earlier and more widespread without serum. The addition of serum had an impressive effect on epibolization. In the absenee of serum, the formation of the epibolus was not only minimal, but also, susceptible to degeneration, and no epibolus remained at 10 days rif incubation. No difference can be found between fetal calf serm and autologous human serum in the formation of the epibolus. There was no favorable effect of serum on the formation of new stratum corneum. The thickness of new straturn corneum increased in parallel with the number of parakeratatic cells, increasing most rapidly between 6 and 8 days of incubation. Parakeratosis was more prominent in the presence of serurn.
Adult ; Biology ; Epidermis ; Humans* ; Organ Culture Techniques* ; Parakeratosis ; Pharmacology ; Selective Estrogen Receptor Modulators ; Skin* ; Toxicology

OBJECTIVES: Isoflavone is a plant-derived compound, abundant in soy food, and its character is mixed estrogenic and antiestrogenic action, so it is highlighted as an alternative to hormone replacement therapy (HRT) in postmenopausal women. The purpose of this study is to establish a foundation for isoflavone study in the future, by estimating isoflavone intake in postmenopausal women and by recommending proper isoflavone intake. METHODS: Isoflavone intake was estimated in a total of 189 Korean postmenopausal women over 50 years old, by using a food frequency questionnaire (FFQ). Data were statistically analyzed by t-test, and one-way ANOVA with Turkey's test. RESULTS: The daily average isoflavone intake level was 21.94 +/- 19.96 mg. There is no significant difference in isoflavone intake according to age. About 60 percentile of postmenopausal women intake isoflavone under 20 mg a day, and 2 percentile of postmenopausal women intake about 80 mg isoflavone. CONCLUSION: There was no definite precise amount of isoflavone for reliving postmenopausal symptom and health. But through this study, most postmenopausal women did not intake enough isoflavone, so they have to intake more isoflavone.
Estrogen Receptor Modulators ; Estrogens ; Female ; Hormone Replacement Therapy ; Humans ; Isoflavones ; Phytoestrogens ; Postmenopause ; Soy Foods ; Surveys and Questionnaires

Adenosarcoma of the uterus is a rare biphasic tumor containing benign glandular epithelial and malignant mesenchymal components. The tumor has been reported to be associated with antiestrogen therapy, particularly tamoxifen, but there have been a few case reports with MRI. We present two cases of MRI findings of uterine adenosarcoma after antiestrogen therapy, tamoxifen and toremifene in breast cancer patients. The tumor presents as a large polypoid mass occupying the endometrial cavity, and may protrude into the vagina. On MRI, the tumor typically shows solid components with scattered small cysts and heterogeneous enhancement. These findings are not significantly different from conventional adenosarcoma.
Adenosarcoma* ; Breast Neoplasms ; Estrogen Receptor Modulators ; Humans ; Magnetic Resonance Imaging* ; Tamoxifen ; Toremifene ; Uterus ; Vagina

OBJECTIVE: To determine the effects of a selective estrogen receptor modulator (SERM), raloxifene, on endometrium in postmenopausal women. METHODS: Double-blind randomized controlled study was designed for 138 healthy postmenopausal women to determine the effects of raloxifene on postmeonopausal endometrium. The women were randomly assigned to receive either placebo, or raloxifene HCl 60 mg/day for 6 months. Transvaginal ultrasound was done at baseline and at 6 months later. RESULTS: Mean endometrial thickness of normal postmenopausal women was 3.4 ( +/- 1.6) mm. Mean endometrial thickness was decreased by 0.2 mm in both groups, but with no statistical significance. CONCLUSION: Raloxifene 60 mg/day did not stimulate the endometrium after 6 months of use in postmenopausal women.
Endometrium* ; Female ; Humans ; Postmenopause ; Raloxifene Hydrochloride* ; Selective Estrogen Receptor Modulators ; Ultrasonography

Antiestrogens have been widely used in the treatment of breast cancer patients. Although tamoxifen is one of the most prevalent antiestrogens, some reported its hepatocarcinogenic effects and the long-term treatment may increase the risk of endometrial and gastrointestinal cancer. Toremifene is an interesting new antiestrogen and have a similar antitumor efficacy as tamoxifen, with less side-effect including less uterotrophic effect compared to tamoxifen, in mice. we report a case of endometrial polyp which were associated with toremifene use, in postmenopausal woman with breast cancer, with a brief review of literature.
Animals ; Breast Neoplasms ; Estrogen Receptor Modulators ; Female ; Gastrointestinal Neoplasms ; Humans ; Mice ; Polyps* ; Tamoxifen ; Toremifene

This work describes tamaoxifen, a nonsteroidal antiestrogen compound, which has been used extensively in the treatment of breast cancer on account of its efficacy and relatively low toxicity. It has been reported to inhibit glioma proliferation in all cell line tested, acting by a mechanism independent of estrogen receptor blockade. Tamoxifen causes cytotoxicity at higher concentration(>or=5 micrometer), as compared with control. Our results showed that this compound decreased the rate of cell proliferation in dose-dependent manner. Its treatment against the C6 glioma cells also resulted in enhancement of the antitumor effect. These data suggest that tamoxifen may serve as an useful agent in chemotherapy of glioma.
Breast Neoplasms ; Cell Line ; Cell Proliferation ; Drug Therapy ; Estrogen Receptor Modulators ; Estrogens ; Glioma* ; Tamoxifen*

Neurological diseases include a variety of neurodegenerative diseases and other brain damage diseases.The treatment schemes for neurological diseases are still in research.The existing clinical and basic studies have confirmed that traditional estrogen therapy has certain protective effect on the nervous system,while it increases the risk of breast or endometrial cancer.The emergence of the selective estrogen receptor modulators (SERMs) can avoid the above mentioned problems.The available studies have confirmed the protective effect of tamoxifen as a SERM on the nervous system.This paper reviews the role and functioning mechanisms of tamoxifen in the nervous system and cognitive function,aiming to provide guidance for the future application of tamoxifen in the treatment of neurological diseases and the improvement of cognitive function.
Tamoxifen/therapeutic use* ; Selective Estrogen Receptor Modulators/therapeutic use* ; Cognition ; Nervous System